Burjeel Holdings is committed to the highest levels of governance and in 2022 appointed a Board of Directors with significant international industry and governance experience to help guide the company through its next phase of expansion. This Board of Directors is supported by an Audit Committee, a Nomination and Remuneration Committee and a Clinical and Medical Advisory Committee.

The Clinical and Medical Advisory Committee will provide support and advice to the Board in relation to programs for clinical pathways, the standardisation of care, the identification of best-practice standards, quality and patient safety related KPIs and quality improvement programs. It shall also support and advise on training, mentoring and development, and provide a connection to, and ongoing exchange of information and ideas with, practitioners in the field and other external contacts.

Across all its brands and businesses, Burjeel Holdings has implemented effective and transparent governance frameworks, in line with best in class standards and regulatory requirements.